Corcept Therapeutics Incorporated (NASDAQ: CORT) is a Healthcare company (Medical - Pharmaceuticals) with a market capitalization of $7.7B. The Maz Rating grades it against the other companies in its sector.
Corcept Therapeutics Incorporated's current Maz Rating and its five factor grades are for members: log in to see them.
At $70.07, Corcept Therapeutics Incorporated trades at 46.5x trailing earnings, 7.9x sales and 8.9x book value, with an EV/EBITDA of 56.3. Over the last twelve months it generated about $967M of revenue and $165M of net income. It runs a gross margin of 98.5%, an operating margin of 11.5% and a net margin of 16.8%. It shows return on equity of 22.9%, return on invested capital of 12.9% and a free cash flow yield of 2.5%. On the balance sheet: a debt-to-equity ratio of 0.01 and a current ratio of 3.00. Over the past 52 weeks the share price ranged from $28.66 to $126.38, with a beta of 0.45.
Corcept Therapeutics Incorporated does not currently pay a dividend.
26 Wall Street analyst ratings cover the stock: 14 Buy, 9 Hold and 3 Sell, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.